Emerging pharmacotherapies, including statins, PPAR-γ agonists, GLP-1RAs, RASIs, and SGLT-2I, have demonstrated multi-target metabolic effects and clinical efficacy in both MAFLD and CKD. Here, PPARG is linked to chronic kidney disease.